GvL effects in T-prolymphocytic leukemia

• Verfasst von: Sellner, Leopold [VerfasserIn]
• Verfasst von: Rieger, Michael [VerfasserIn]
• Verfasst von: Dietrich, Sascha [VerfasserIn]
• Verfasst von: Luft, Thomas [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Titel: GvL effects in T-prolymphocytic leukemia
• Titelzusatz: evidence from MRD kinetics and TCR repertoire analyses
• Verf.angabe: L. Sellner, M. Brüggemann, M. Schlitt, H. Knecht, D. Herrmann, T. Reigl, A. Krejci, V. Bystry, N. Darzentas, M. Rieger, S. Dietrich, T. Luft, A. D. Ho, M. Kneba and P. Dreger
• Jahr: 2017
• Jahr des Originals: 2016
• Umfang: 8 S.
• Teil: volume:52
• Teil: year:2017
• Teil: number:4
• Teil: pages:544-551
• Teil: extent:8
• Fussnoten: Published online: 12 December 2016 ; Gesehen am 04.07.2018
• Titel Quelle: Enthalten in: Bone marrow transplantation
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2017
• Band/Heft Quelle: 52(2017), 4, Seite 544-551
• ISSN Quelle: 1476-5365
• DOI: doi:10.1038/bmt.2016.305
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Errata: Sellner, Leopold, 1984 - : Corrigendum: GvL effects in T-prolymphocytic leukemia
• K10plus-PPN: 1577287401

Abstract

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses

Abstract

Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD) kinetics with immune interventions and T-cell receptor (TCR) repertoire diversity alterations in patients after alloSCT for T-PLL. Longitudinal quantitative MRD monitoring was performed by clone-specific real-time PCR of TCR rearrangements (n=7), and TCR repertoire diversity assessment by next-generation sequencing (NGS; n=3) Although post-transplant immunomodulation (immunosuppression tapering or donor lymphocyte infusions) resulted in significant reduction (>1 log) of MRD levels in 7 of 10 occasions, durable MRD clearance was observed in only two patients. In all three patients analyzed by TCR-NGS, MRD responses were reproducibly associated with a shift from a clonal, T-PLL-driven profile to a polyclonal signature. Novel clonotypes that could explain a clonal GvL effect did not emerge. In conclusion, TCR-based MRD quantification appears to be a suitable tool for monitoring and guiding treatment interventions in T-PLL. The MRD responses to immune modulation observed here provide first molecular evidence for GvL activity in T-PLL which, however, may be often only transient and reliant on a poly-/oligoclonal rather than a monoclonal T-cell response.